Diagnostic Imaging Drug Development Expertise

From lab to market

We provide full-service Imaging Diagnostics Clinical Development, from pre-clinical to IND and NDA submission and Medical Affairs.

We have developed current market leaders

We have led 7 imaging new drug approvals globally: MRI, CT, and radiopharmaceuticals.

Literature-based approvals

Utilizing only existing literature reviews, we have gained 5 new indications for imaging drugs without performing additional clinical trials.

Over 40 years of experience

Between our two RadMD principals, there are over 40 years of contrast agent development experience.

Imaging management solutions

Our full-service imaging management solutions provide a comprehensive set of services to support pharmaceutical, medical device and AI companies with their clinical trials.


Our reader group

We are the global leader in providing consultants to perform imaging BICR (blinded independent central reviews)


Diagnostic Imaging Drug Development Expertise

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.


We have 12 years of experience in comprehensive sourcing and management of our readers for over 600 trials.

Read our case studies

Let’s work together

Contact us

Latest News

Co-Founder Dr Kohkan Shamsi confirmed as RSNA 2022 speaker

Dr Kohkan Shamsi, RadMD co-founder, has been confirmed as a speaker for RSNA 2022 Dr Shamsi is booked to discuss “The Effect of Food Intake on Pharmacodynamics of A Novel Oral Liver-specific…


Clinical Evidence Supports Dotarem® Injection for MR Imaging

New Article in Applied Radiology, the Journal of Practical Medical Imaging and Management: Magnetic resonance imaging (MRI) contrast agents are widely used to increase the contrast difference between…


RadMD managed imaging for a phase II trial for Ipsen biopharmaceuticals’ new Gallium PET imaging agent

RadMD managed imaging for a phase II trial for Ipsen biopharmaceuticals’ new Gallium PET imaging agent to assess somatostatin receptor (SSTR2) positive gastroenteropancreatic neuroendotrine tumor…


View All